Biotechnology

Cardinal Health Inc., during the quarter ended June 30, 2008, received the remaining US$35.0 million in net proceeds from the settlement of the derivative actions filed against the Company and certain of its directors and officers.

On Nov. 8, 2002,…

Valeant Pharmaceuticals International, in its Form 10-Q dated Aug. 11, 2008, disclosed that it expects to be dismissed with prejudice from Kathleen M. O’Connor’s product liability lawsuit on Permax soon.

On Feb. 8, 2007, the Company was served with the…

Cardinal Health Inc. and the Drug Enforcement Administration of the U.S. Department of Justice, on Aug. 7, 2008, reached an oral agreement in principle to resolve the license suspensions.

The agreement is subject to the completion of definitive documentation as…